Patient characteristics

Mel number	Sex	Successful expansion (N = 29)	Tumor-reactive (N = 21)	FFPE (N = 17)	Site	Time to growth (days)
Mel-119	M	No			Right Groin
Mel-120	F	No
Mel-131	M	Yes	Yes		Right Back	29
Mel-133	M	Yes	Yes	FFPE	Liver	30
Mel-134	M	Yes	Yes			38
Mel-135	F	No		FFPE	Right supraclavicular mass
Mel-140	F	Yes	No			37
Mel-144	M	No		FFPE	Intraperitoneal mass
Mel-145	M	Yes	Yes			27
Mel-150	F	No			Right back mass
Mel-160	F	Yes	Yes	FFPE	Right Thigh	26
Mel-163 A	F	Yes	Yes	FFPE	Illiac LN	55
Mel-173-C	5 F	Yes	Yes	FSC		40
Mel-176	M	Yes	Yes	FFPE	lower left lobe	34
Mel-177A	F	Yes	Yes	FSC	Right Leg mass	25
Mel-179	F	Yes	No	FSC	Right axillary mass	56
Mel-180A	M	Yes	Yes		Axillary tumor mass	40
Mel-181	F	Yes	Yes			12
Mel-182	M	No		FFPE	Left pelvic mass
Mel-185	M	Yes	Yes	FSC	Superior medistinal mass	33
Mel-186	M	No		FSC	Right lower lobe mass
Mel-187	M	Yes	No		Paracenthesis fluid	67
Mel-188	M	Yes	No	FFPE	Right Axillary LN	41
Mel-189	M	No			Left Chest wall
Mel-189A	M	Yes	Yes			32
Mel-190	M	No		FFPE	Small Bowl
Mel-191	M	Yes	No		LN	28
Mel-192	F	No			Thigh
Mel-193	F	No			Left Lung Upper Lobe
Mel-199	M	Yes	Yes	FSC		48
Mel-200	M	Yes	Yes	FSC	Left lower tumor	37
Mel-201	M	Yes	Yes			26
Mel-206	M	Yes	Yes			56
Mel-207	M	Yes	Yes			35
Mel-208	M	Yes	Yes		Left lower lobe LN	33
Mel-209	M	Yes	Yes	FFPE	Liver mass	29
Mel-211	F	Yes	Yes		Liver mass	26

Tumor specificity is determined by IFN-γ release when stimulated with the autologous tumor cell line or tumor digest (defined as IFN-γ release greater than 100 pg/ml and double the background (T cells alone). FFPE or FSC (frozen section control) samples are available where indicated. The letters (A, B, C) after Mel-# designate tumors from different sites